Safety analysis following tacrolimus immunosuppression in renal transplant recipients in Japan: 3-year results in over 1000 patients
この論文をさがす
説明
TTACROLIMUS is a potent immunosuppressant that is now well established for primary immunosuppression in kidney transplantation as well as in other solid organ transplantations, with long-term clinical experience accumulating. In Japan, tacrolimus was approved for the prevention of allograft rejection in patients receiving kidney transplants in April 1996. Since then, it has been used widely in various recipient and donor conditions. This paper summarizes the results of a 3-year experience with tacrolimus at 35 leading institutions for renal transplantation in Japan, focusing on safety data for tacrolimus with special attention to its effects on cardiovascular risk factors.
収録刊行物
-
- Transplantation Proceedings
-
Transplantation Proceedings 34 1600-1603, 2002-08-01
Elsevier BV
